安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- RYTELO® (imetelstat) HCP Website | RYTELOHCP
RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- Homepage - Rytelo Patient
RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults: with anemia (low red blood cell counts) who need blood transfusions of 4 or more red blood cell units over 8 weeks
- Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs. com
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- label - Food and Drug Administration
RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution
- Rytelo (imetelstat): Uses, Side Effects, Interactions, Pictures . . . - WebMD
Find patient medical information for Rytelo (imetelstat) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Rytelo: Dosage, side effects, uses, interactions, cost, and more
Rytelo (imetelstat) is a prescription intravenous infusion for a certain group of blood cancers Learn about dosage, side effects, and more
- Rytelo, INN-imetelstat sodium
Rytelo works by blocking an enzyme (protein) called ‘telomerase’ that helps cancer cells grow and divide This stops the growth of abnormal cancer cells in the bone marrow and allows your bone marrow to make normal blood cells, which may make you feel less tired
- Rytelo (Imetelstat for Injection): Side Effects, Uses, Dosage . . . - RxList
Rytelo (imetelstat) is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoies
|
|
|